Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial
John W. Ostrominski(Brigham and Women's Hospital), Scott D. Solomon(Brigham and Women's Hospital), Brian Claggett(National Heart Lung and Blood Institute), Anna Maria Langkilde(British Heart Foundation), Adrian F. Hernandez(Duke University), Pardeep S. Jhund(Copenhagen University Hospital), John J.V. McMurray(Western Infirmary), Senthil Selvaraj(Duke University), Rudolf A. de Boer(University Medical Center Groningen), Felipe A. Martínez(Universidad Nacional de Córdoba), Mikhail Kosiborod(Copenhagen University Hospital), Muthiah Vaduganathan(Harvard University), Carolyn S.P. Lam, Magnus Petersson(AstraZeneca (Sweden)), Zi Michael Miao(Brigham and Women's Hospital), Silvio E. Inzucchi(Yale University), Akshay S. Desai(Brigham and Women's Hospital), Sanjiv J. Shah(National Heart Lung and Blood Institute)
Cited by 20
Related Papers
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
|New England Journal of Medicine|2015|11.9k
Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology
|Journal of the American Society of Echocardiography|2005|11.3k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k